Zafgen Added to NASDAQ Biotechnology Index

Zafgen Announces Initiation of Phase 2b Trial of Beloranib in Severe Obesity

Voyager Therapeutics and MassBiologics Announce Strategic Collaboration for Viral Vector Manufacturing

Rhythm Appoints Fred T. Fiedorek, M.D., Chief Medical Officer

Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock

Agios Pharmaceuticals Announces Proposed Offering of Common Stock

Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors

New Clinical Data Supports the Use of FoundationOne® Heme to Enable Informed Treatment Decisions in a Wide Range of Hematologic Malignancies

FoundationOne® Identifies Clinically Relevant Genomic Alterations in Patients with Advanced Breast Cancers

Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting

bluebird bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are Transfusion-Free

Global Blood Therapeutics’ GBT440 Demonstrates Ability to Positively Impact Fundamental Sickle Cell Disease (SCD) Processes in Studies Presented at 2014 American Society of Hematology (ASH) Conference

Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency

Agios Announces Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to April 2016

Treatment for Relapsed Multiple Myeloma Patients Guided by FoundationOne® Heme Results in Promising Clinical Activity

Ablexis Announces Availability of the AlivaMab Mouse Technology and Settlement of the Litigation with Regeneron Pharmaceuticals, Inc.

Allena Pharmaceuticals Secures $25 Million Series B Financing

NinePoint Medical Appoints Christopher von Jako, Ph.D., to Chief Executive Officer

Afferent Pharmaceuticals Announces the Election of Dr. Peter Hirth to the Company’s Board of Directors

Foundation Medicine Appoints David J. Daly as Chief Commercial Officer

Foundation Medicine and Flatiron Health Collaborate to Develop First-in-Class Data Platform to Accelerate Precision Medicine for Cancer

Global Blood Therapeutics to Present New Data Highlighting Therapeutic Potential of GBT440 in Sickle Cell Disease (SCD) at 2014 American Society of Hematology (ASH) Conference

Nurix Launches Collaboration with Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute to Expand its Drug Discovery Program

Editas Medicine Licenses Genome Editing Technology from Broad Institute and Harvard University

Editas Medicine Licenses Genome Editing Technology from Massachusetts General Hospital

Eleven Biotherapeutics to Present at Oppenheimer 25th Annual Healthcare Conference

Eleven Biotherapeutics Announces Additional Financing of $20 Million

Foundation Medicine to Present at the Piper Jaffray Healthcare Conference

Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published in The Lancet

Blueprint Medicines Unveils New Drug Discovery Program for Patients with RET Fusions at 26th EORTC-NCI-AACR Symposium

Foundation Medicine\'s Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis Oncology\'s PARP inhibitor, Rucaparib

Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)

Blueprint Medicines to Present Discovery of New Cancer Drug Targets at EORTC-NCI-AACR Symposium

Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results

bluebird bio Reports Fiscal Third Quarter 2014 Financial Results

Blueprint Medicines Secures $50 Million in Series C Financing

The Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute Partner with Foundation Medicine to Launch Innovative Clinical Translation Program

Zafgen Reports Third Quarter 2014 Financial Results

SAGE Therapeutics Reports Third Quarter 2014 Results

Allena Pharmaceuticals To Present Data on Lead Program ALLN-177 at ASN Kidney Week 2014

James M. DeTore joins bluebird bio as Chief Financial Officer

SAGE Therapeutics Reports Positive Top-Line Phase 2 Data of SAGE-547 in Patients With Super-Refractory Status Epilepticus

bluebird bio to Present at Three Upcoming Health Care Conferences

Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results

SAGE Therapeutics Announces Six Scientific Presentations at Neuroscience 2014, the Society for Neuroscience\'s 44th Annual Meeting

Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting

bluebird bio to Present LentiGlobin Clinical Data at the American Society of Hematology Conference

Foundation Medicine Announces 2014 Third Quarter Results and Recent Highlights

SAGE to Present at Credit Suisse 23rd Annual Healthcare Conference

Eleven Biotherapeutics to Report Third Quarter 2014 Financial Results on November 13, 2014